Myelolipoma: an unusual differential of duodenal polyp

Arkadeep Dhali, Sukanta Ray, Dijendra Nath Biswas, Gopal Krishna Dhali

DESCRIPTION

Polypoidal lesions of the duodenum comprises close differentials like a gastrointestinal stromal tumour, Brunner’s gland hamartoma, adenocarcinoma, lymphoid, carcinoid, neuroendocrine tumour and other neuroblastic tumours. Myelolipoma on the other hand predominantly arises from the adrenal gland. Although few cases of extra-adrenal myelolipomas are reported, they were found to originate from the presacral region, liver, gastric antrum, mediastinum, pleura and retroperitoneum, with the most common extra-adrenal site being the presacral area. To the best of our knowledge, there are no cases reported in the existing medical literature on myelolipoma arising from the duodenum and this is the first case reported.

We report a 40-year-old woman, who presented to our outpatient clinic with a history of haematemesis for 5 days and melena for 8 days. She also complained of mild abdominal discomfort, loss of appetite and weight loss since the last 4 months. Pallor was present and rest of the physical examination was unremarkable. Her haemoglobin was 6.5 gm/dL and was treated with three units of blood transfusion. Posttransfusion haemoglobin was 12 gm/dL. Upper gastrointestinal (UGI) endoscopy was performed, which revealed a sessile polypoidal swelling with a smooth surface and a large base in the first part of the duodenum measuring >2 cm in the posterior wall of the duodenal bulb (figure 1A). There was no visible ulcer or bleeding from the lesion at the time of evaluation. To characterise the lesion better and to know the layer of origin, endoscopic ultrasound (EUS) was performed (figure 1B), which revealed a 2.4 cm hyperechoic, submucosal lesion with no calcification, cystic change or ductal structure and (C) contrast-enhanced CT showing a heterogeneously enhancing polypoidal mass arising from the posterior wall of duodenal bulb measuring 2.4 × 2 × 2 cm with no periduodenal fat stranding.

Operative time was 125 min and operative blood loss was 200 mL. The resected specimen was sent for histopathological examination, which showed an admixture of mature adipose tissue interspersed with trilineage haematopoietic cells. Individual

© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Dhali A, Ray S, Biswas DN, et al. BMJ Case Rep 2021;14:e246444. doi:10.1136/bcr-2021-246444
adipocytes were large, round with eccentrically placed small nuclei and abundant clear cytoplasm. Overall, it was suggestive of myelolipoma (figure 2A,B). The postoperative period was uneventful, and she was doing well on an 18-month follow-up.

Polyoidal lesions of the duodenum are known to cause UGI haemorrhage and present as described above. The histopathological diagnosis of myelolipoma from an unusual location was unique in this case. Extra-adrenal myelolipoma comprises 14% of all myelolipomas. Proposed theories for its etiopathogenesis are embolisation of haematopoietic components from bone marrow tissue, or reactivation of embryonic peritoneal connective tissue in response to a triggered stimulus, like an endocrine dysfunction or a septic condition. Generally, these tumours are asymptomatic and do not require any intervention, but may turn symptomatic if it is large enough to cause mass effect or bleeding-induced complications. In most cases, they are picked up incidentally by radiological investigations. A typical contrast-enhanced CT describes it as a heterogenous (admixture of fat tissue and other soft tissue), well-circumscribed hypodense lesion (<10 HU). With these radiological features, differentials are myelolipoma, lipoma, liposarcoma, teratoma and even extramedullary haematopoiesis. Due to their benign nature, asymptomatic tumours and lesions <6 cm do not require any form of intervention and an annual imaging surveillance is advised. In our case, not only was it symptomatic, but also we did not even had a preoperative diagnosis. This may be attributed to the small size of the tumour which did not fit into the typical radiological description. Moreover, the UGI endoscopic findings of a polypoidal lesion with smooth overlying mucosa were pointing more towards common pathological entities like Brunner’s gland hamartoma or gastrointestinal stromal tumour. The EUS-guided FNA sampling was also inadequate in our case. Hence we managed it as a benign duodenal polyp and it was adequate. Our own unit does not have experience in advanced EUS techniques or advanced laparoscopic techniques, and hence we chose to remove the polyp at an open procedure. But, other centres might have approached the excision in other ways.

Histopathological evaluation stays the gold standard investigation, where mature adipose tissue interspersed with haematopoietic cells are seen. Hence, clinicians should be aware of this rare pathological entity which can mimic other common differentials of polyoidal lesions of duodenum. Moreover, biopsy and histological examination is essential for diagnosis to differentiate myelolipomas from other benign and malignant lesions as the treatment and outcome change accordingly.

**Contributors**  AD: Conception, design of the study, acquisition of the data, drafting the manuscript and final approval of the version to be submitted. SR: Conception, design of the study, acquisition of the data, drafting the manuscript and final approval of the version to be submitted. DNB: Acquisition of the data, final approval of the version to be submitted.

**Funding**  The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**  None declared.

**Patient consent for publication**  Consent obtained directly from patient(s).

**Provenance and peer review**  Not commissioned; externally peer reviewed.

Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

**ORCID iDs**
Arkadeep Dhali http://orcid.org/0000-0002-1794-2569
Dijendra Nath Biswas http://orcid.org/0000-0002-0997-3991

**REFERENCES**